Shanghai Biotech Firm Wins Approval For Cutting-Edge Melanoma Drug
Shanghai Junshi Biosciences Co. Ltd. has won approval to launch a novel cancer drug in China, where it will compete with two U.S. rivals.
The injectable medicine belongs to a class of drugs known as PD-1 inhibitors, which work by reversing the cancer’s suppression of a patient’s immune system and help the immune system target cancer cells.
The drug, which is used to treat certain types of melanoma, received a green light from National Medicine Products Administration on Monday, the regulator said (link in Chinese).
- 1China’s Moon Explorer Posts Photo of Sprouting Cotton Plant
- 2Huawei Canada Exec Quits as Scandal Continues to Embroil Company
- 3Luckin Coffee Reportedly Seeks IPO in Hong Kong
- 4Bank of China to Test Waters for Perpetual Bonds
- 5Apple Chief Counsel Accuses Qualcomm of Holding Phone-Makers for ‘Ransom’
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas